Sunshine Current Deferred Revenue from 2010 to 2025
| SBFMW Stock | USD 0.24 0.04 20.00% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 344.8 K | Current Value 192.1 K | Quarterly Volatility 127.2 K |
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
Sunshine | Current Deferred Revenue |
Latest Sunshine Biopharma's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Sunshine Biopharma Warrant over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Sunshine Biopharma's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Sunshine Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 155,025 | |
| Geometric Mean | 106,617 | |
| Coefficient Of Variation | 82.07 | |
| Mean Deviation | 118,886 | |
| Median | 49,349 | |
| Standard Deviation | 127,230 | |
| Sample Variance | 16.2B | |
| Range | 295.5K | |
| R-Value | 0.81 | |
| Mean Square Error | 5.9B | |
| R-Squared | 0.66 | |
| Significance | 0.0001 | |
| Slope | 21,692 | |
| Total Sum of Squares | 242.8B |
Sunshine Current Deferred Revenue History
About Sunshine Biopharma Financial Statements
Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 344.8 K | 192.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.